

company announcement

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 6 August 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	DÉSIRÉE JANTZEN ASGREEN	
2	Reason for the notification		
a)	Position/status	Member of the Board of Directors	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 294.30	74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	ELISABETH DAHL CHRISTENSEN	
2	Reason for the notification		
a)	Position/status	Member of the Board of Directors	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s) DKK 294.30	Volume(s) 74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	METTE BØJER JENSEN	
2	Reason for the notification		
a)	Position/status	Member of the Board of Directors	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s) DKK 294.30	Volume(s) 74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	SEMSI KILIC MADSEN	
2	Reason for the notification		
a)	Position/status	Member of the Board of Directors	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s) DKK 294.30	Volume(s) 74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	EMIL KONGSHØJ LARSEN	
2	Reason for the notification		
a)	Position/status	Executive Vice President, International Operations	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 294.30	74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	KARSTEN MUNK KNUDSEN	
2	Reason for the notification		
a)	Position/status	Executive Vice President, Chief Financial Officer (CFO)	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 294.30	74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	KASPER BØDKER MEJLVANG	
2	Reason for the notification		
a)	Position/status	Executive Vice President, Global Manufacturing & Supply	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 294.30	74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	MAZIAR MIKE DOUSTDAR	
2	Reason for the notification		
a)	Position/status	President and CEO	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 294.30	74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	MARTIN HOLST LANGE	
2	Reason for the notification		
a)	Position/status	Executive Vice President, R&D and Chief Scientific Officer (CSO)	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 294.30	74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	THILDE GYNTH BØGEBJERG KRØYER	
2	Reason for the notification		
a)	Position/status	Executive Vice President, Enterprise IT & Quality	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 294.30	74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	TANIA SABROE	
2	Reason for the notification		
a)	Position/status	Executive Vice President, People, Organisation & Corporate Affairs	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0062498333	
b)	Nature of the transaction	Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100 th Anniversary Shares)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 294.30	74
d)	Aggregated information - Aggregated volume - Price	74 shares DKK 21,778.20	
e)	Date of the transaction	2026-08-05	
f)	Place of the transaction	Outside a trading venue	

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

Contacts for further information

Media:

Ambre James-Brown

+45 3079 9289

abmo@novonordisk.com

Liz Skrbkova (US)

+1 609 917 0632

lzsk@novonordisk.com

Investors:

Michael Novod

+45 3075 6050

nvno@novonordisk.com

Sina Meyer

+45 3079 6656

azey@novonordisk.com

Alex Bruce

+45 3444 2613

axe@novonordisk.com

Mads Berner Bruun

+45 3075 2936

mbbz@novonordisk.com

Christoffer Togo Solgaard-Tullin

+45 3079 1471

cftu@novonordisk.com

Ida Schaap Melvold

+45 3077 5649

idmg@novonordisk.com

Frederik Taylor Pitter (US)

+1 609 613 0568

fp@novonordisk.com